De Vré will join the group as CEO elect on April 1, 2021 and will work alongside Salik during a transition period prior to taking up his role as CEO over the course of the summer. Salik will remain a member of the Executive Committee until the summer of 2021.

During the past 8 years, De Vré has worked at Dr. Reddy's Laboratories, where he currently is a member of the Management Council and Global Head of Biologics. Prior to this, he spent 15 years with McKinsey, where he was a Partner advising pharmaceutical, biotech and specialty chemical companies in Europe, the US and India. De Vré is a Belgian national and holds a master’s degree in engineering from Université Libre de Bruxelles (ULB) as well as a PhD in applied physics from Stanford University.